BUSINESS
Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
Boehringer Ingelheim’s Japan pharma arm plans to make oncology one of the pillars of its domestic business, beginning with the launch of its anticancer agent Hernexeos (zongertinib) earlier this month. Speaking to Jiho on November 18, Masataka Ogimura, president of…
To read the full story
Related Article
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
BUSINESS
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





